These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21592727)

  • 1. Too many cohorts and repeated measurements are a waste of resources.
    Tekle FB; Tan FE; Berger MP
    J Clin Epidemiol; 2011 Dec; 64(12):1383-90. PubMed ID: 21592727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-optimal cohort designs for linear mixed-effects models.
    Tekle FB; Tan FE; Berger MP
    Stat Med; 2008 Jun; 27(14):2586-600. PubMed ID: 17726724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactive computer program for optimal designs of longitudinal cohort studies.
    Tekle FB; Tan FE; Berger MP
    Comput Methods Programs Biomed; 2009 May; 94(2):168-76. PubMed ID: 19131139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal designs for empirical bayes estimators of individual linear and quadratic growth curves in linear mixed models.
    Candel MJ
    Stat Methods Med Res; 2009 Aug; 18(4):397-419. PubMed ID: 19036913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal designs for clinical trials with second-order polynomial treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Stat Methods Med Res; 2007 Dec; 16(6):523-37. PubMed ID: 17698939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal number of repeated measures and group sizes in clinical trials with linearly divergent treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Contemp Clin Trials; 2006 Feb; 27(1):57-69. PubMed ID: 16260188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-efficient designs of cluster unit trials.
    McKinlay SM
    Prev Med; 1994 Sep; 23(5):606-11. PubMed ID: 7845924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of repeated-measures analysis of variance and hierarchical linear model in nursing research.
    Shin JH
    Nurs Res; 2009; 58(3):211-7. PubMed ID: 19448525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Roaming through methodology. XXVII. Problems with longitudinal studies: confounding of the relationship between age, time of measurement and birth cohort].
    Kemper HC
    Ned Tijdschr Geneeskd; 2000 Nov; 144(47):2247-51. PubMed ID: 11109468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunity cost: a systematic application to surgery.
    Chatterjee A; Payette MJ; Demas CP; Finlayson SR
    Surgery; 2009 Jul; 146(1):18-22. PubMed ID: 19541006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling and design of cross-over trials.
    Jones B; Donev AN
    Stat Med; 1996 Jul; 15(13):1435-46. PubMed ID: 8841653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal time-points in clinical trials with linearly divergent treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Stat Med; 2005 Dec; 24(24):3743-56. PubMed ID: 16320272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
    Liang Y; Carriere KC
    Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.
    Müller HH; Pahl R; Schäfer H
    Genet Epidemiol; 2007 Dec; 31(8):844-52. PubMed ID: 17549751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designs for dose-escalation trials with quantitative responses.
    Bailey RA
    Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.